Haemonetics | 8-K: Current report
Haemonetics | 8-K: Current report
Haemonetics | 8-K: Current report
Haemonetics | SC 13G: Statement of acquisition of beneficial ownership by individuals-T. Rowe Price Investment Management, Inc.(5.6%)
Haemonetics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital Research Global Investors(8.7%)
Haemonetics | 144: Notice of proposed sale of securities pursuant to Rule 144
Haemonetics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Wellington Management Group LLP(8.27%),Wellington Group Holdings LLP(8.27%), etc.
Haemonetics | 10-Q: Q2 2025 Earnings Report
Haemonetics | 8-K: Haemonetics Reports Second Quarter and First Half Fiscal 2025 Results; Updates Fiscal 2025 Guidance
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Officer Galvin Roy
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Officer Miller Laurie A.
Haemonetics | 8-K: Current report
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Officer Simon, Christopher
Haemonetics | 10-Q: Q1 2025 Earnings Report
Haemonetics | 8-K: Haemonetics Reports First Quarter Fiscal 2025 Results; Reaffirms Fiscal 2025 Guidance
Haemonetics | 8-K/A: Current report (Amendment)
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Officer Strong Stewart W
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Officer Strong Stewart W
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Director Bryant Diane M
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Director COYLE MICHAEL J